Our study’s aim was to evaluate whether information provided
by MRimaging measurements of “final” cerebral infarct
volume could be assessed as early as the subacute stage (days
3–6), rather than waiting for the chronic stage (days 30–45),
thereby leading to an earlier outcome marker.